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health (PSH) proﬁle, were analyzed. RESULTS: A total of 131
patients were included in the waiting-list and 80% received a
kidney transplant, 41% were ECD. Sixty percent were men. The
age difference between ECD, SCD and not transplanted was
signiﬁcant (p = 0.000). The mean time in waiting-list (15 months)
and cold ischemia time (14 hours) were the same for both groups.
There were no differences in clinical variables. The PSH improve-
ment in ECD at year was signiﬁcant (p = 0.022), whereas for the
SCD not. There were differences in incomes (p = 0.041) between
groups. The survival at ﬁrst year was 100% for SCD and 97.7%
for ECD. At year, mean cost for SCD transplant was €54,343/year
versus €59.13€/year for ECD (no signiﬁcant). The difference in
QALYs between transplanted ones and not-transplanted was
signiﬁcant (p = 0.019). The utility was: 0.8096 QALYs for SCD,
0.7786 for ECD and 0.6838 for not transplanted. Cost-utility
analysis showed that one QALY in SCD cost €67.27€, versus
€79.95€/QALY of ECD and €80.43€/QALY of not transplanted in
waiting list. CONCLUSIONS: There were no clinical differences
and not in PSH at the ﬁrst transplant year between SCD and ECD,
but there were in age and what it bears. The differences in terms of
cost-utility, in the ﬁrst year, between ECD and not transplanted
were small. However, the differences could be important in long
term, because after the ﬁrst year the costs have an important
decrease. Therefore, it seems that ECD transplant have a good
results in health and costs.
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OBJECTIVES: To assess the cost and the resource use related to
anaemia management with Aranesp®, Eprex® and Neorecor-
mon(r) in patients with chronic renal failure treated with hae-
modialysis in Belgium; and to assess the effect of anaemia
management on haemoglobin (Hb) levels. METHODS: Data on
anaemia management and resource utilization were collected
using a retrospective chart review conducted in 11 haemodialysis
centres distributed across Belgium. From each centre between 30
and 40 patients were randomly selected. Data on drug use,
transfusion, consultations, hospitalizations, diagnostic tests and
Hb level were collected over a 1-year study period (1 December
2005 until 30 November 2006). The costs were calculated by
multiplying each item of resource use with its unit cost (in 2007;
in €) from the Belgian health care payer’s perspective (RIZIV/
INAMI). RESULTS: A total of 335 patients were included of
which 105, 132 and 98 were treated with Aranesp®, Eprex® and
Neorecormon(r), respectively. There were no demographic dif-
ferences between the treatment arms. There were no statistically
signiﬁcant differences between the 3 ESAs in the total annual
anaemia management cost in haemodialysis treated chronic renal
failure patients despite differences in drug list prices between the
3 ESAs. The cost ranged from €8203 to €9281. There were no
signiﬁcant differences in the average weekly dose of ESA between
the 3 drugs. Independent of the iron status of the patient, or
when stratiﬁed by CRP level, the percentage of patients reaching
a Hb level  11 g/dl was similar in the 3 treatment arms and
ranged from 76% to 81%. CONCLUSIONS: In patients with
chronic renal failure, treated with haemodialysis, there were no
signiﬁcant differences between the 3 available ESAs in medical
resource use, average dose of ESA needed, annual anaemia man-
agement costs from the perspective of the Belgian public health
care payer and in Hb control.
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OBJECTIVES: Due to their duration of action, current erythro-
poietin stimulating agents (ESA) require frequent administrations
(up to 3 injections per week). The objective of this study was a)
to estimate the potential time savings resulting from a switch to
a new once a month CERA (continuous erythropoietin receptor
activator), and b) to determine its beneﬁts in quality of care and
procedural improvements. METHODS: The different stages in
the global ESA Hospital Process (from ordering to invoicing)
were identiﬁed. A time and motion method was used for each
stage to determine the time spent managing ESA in eight dialysis
centres with different proﬁles. Simulations were performed to
assess the time savings according to various levels of the new
product’s penetration rates. Qualitative interviews with the
medical and administrative staff involved in the ESA manage-
ment were carried out to assess the expected beneﬁts of switching
to monthly injections. Intermediary and ﬁnal results were vali-
dated by a Scientiﬁc Committee. RESULTS: Current ESA man-
agement requires between 6 h 12 min and 20 h 36 min per
patient per year. The estimated total time saved by switching
to monthly injections ranged from 5 h 13 min to 17 h 29 min per
patient per year. Pharmacists and nurses are the two staff catego-
ries most affected by the time savings, which are respectively
from 28 min to 13 h and from 51 min to 3 h 32 m per patient
per year. Qualitative interviews supported these results and also
highlighted a potential time savings for administrative staff.
CONCLUSIONS: Administration of a monthly CERA injection
could reduce total time spent on ESA management by up to 85%
(for a total conversion). Time saved would allow the staff
involved to improve both their organisation and procedures
(stock management, outdated products, etc.) and their quality of
care (optimisation for Continuing Professional Development
indicators: patient close monitoring, compliance, etc.).
URINARY/KIDNEY DISORDERS—
Patient-Reported Outcomes Studies
PUK16
EXPLORINGTHE IMPACT OF CHANGES IN NEUROGENIC
URINARY INCONTINENCE FREQUENCY AND CONDITION
SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED
OUTCOMES
Hollingworth W1, Campbell JD2, Kowalski J3, Ravelo A3, Girod I4,
Briggs A5, Sullivan SD2
1University of Bristol, Bristol, UK, 2University of Washington, Seattle,
WA, USA, 3Allergan, Inc, Irvine, CA, USA, 4Allergan Limited, Marlow,
UK, 5University of Glasgow, Glasgow, UK
OBJECTIVES: Many trials do not measure Quality Adjusted Life
Years (QALYs). Therefore decision analysts wishing to extrapo-
late trial results for policy makers often map condition speciﬁc
outcomes to preference scores. We estimated the relationship
between changes in preference scores and commonly reported
condition speciﬁc outcomes in patients with neurogenic urinary
incontinence (UI). METHODS: In 59 patients recruited to a
neurogenic UI randomised controlled trial, clinical outcomes (UI
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